Possible Interaction: Glucose and Ng-Nitroarginine Methyl Ester

“During the OGTT, l-NAME raised 2 h plasma glucose by 1.8 mmol/l (p < 0.01), doubled insulin clearance and impaired beta cell glucose sensitivity while depressing endothelial function.”

“ODQ and the NOS inhibitor, L-NAME (100 microM), decreased basal glucose uptake but did not affect insulin-stimulated glucose transport.”

“ L-NAME caused increase (P<0.05) in levels of glucose , albumin, globulin, creatinine, urea, triglyceride and cholesterol.”

“Supplementation with L-arginine and/or L-NAME decreased levels of glucose in blood serum of animals undergoing ischemia-reperfusion syndrome compared to the control and placebo groups.”

“In contrast, a selective NOS inhibitor such as Nomega-nitro-L-arginine methyl ester (L-NAME) in the STn before CChrc stimulation resulted in an increase of both, systemic glucose and BGR above control values.”

“Injection of L-NAME at 300 mg/kg BW resulted in a significant decrease in the basal glucose uptake in gastrocnemius muscles (P<0.01).”

“ Raising glucose from 2.8 to 11.1 mM augmented NO release by 429+/-133 nM (n=12, P<0.05), an effect blocked by the NO synthase inhibitor L-NAME (n=3).”

“High or low glucose concentrations had no effect on basal NO production or the survival of neurones in culture, but treatment with N‐nitro‐l‐arginine methyl ester reduced extracellular levels of NO and increased neuronal survival at both concentrations of glucose.”

“There was an interaction (P = 0.038) between time and treatment, such that L-NAME initially increased the AVD of glucose (up to 180 m) divergent from control lambs.”

“Abstract—We have reported that glucose infusion in L-NAME –treated rats increased arterial pressure more than the additive responses to glucose and L-NAME alone.”